The IGR-CaP1 xenograft model recapitulates mixed osteolytic/ blastic bone lesions observed in metastatic prostate cancer

Neoplasia (United States)

Volumn 14, Issue 5, 2012, Pages 376-387

  Nakouzi, Nader Al ^a,b   Bawa, Olivia ^a,b   le Pape, Alain ^c,d   Lerondel, Stéphanie ^c   Gaudin, Catherine ^a,b   Opolon, Paule ^a,b   Gonin, Patrick ^a,b   Fizazi, Karim ^a,b   Chauchereau, Anne ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS   (France)

^d Laboratory of Microbiology CNRS UMR 7276 Faculties of Medicine and Pharmacy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HEMOGLOBIN; KI 67 ANTIGEN; MEDRONATE TECHNETIUM TC 99M; OSTEOPONTIN; OSTEOPROTEGERIN; PROTEIN ADAMTS14; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE LESION; BONE METASTASIS; BONE REMODELING; CANCER STEM CELL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IGR CAP1 CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR MODEL;

EID: 84861684338     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12308     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, and Blute ML (2002). Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95, 1028-1036.
3. Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593.
4. Roodman GD (2004). Mechanisms of bone metastasis. N Engl J Med 350, 1655-1664.
5. Jin J-K, Dayyani F, and Gallick GE (2011). Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128, 2545-2561.
6. Seibel MJ (2005). Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2, 504-517.
7. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, and Cher ML (2002). Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94, 17-25.
8. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, and Chung LW (1998). Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigenproducing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77, 887-894.
9. Hall CL, Bafico A, Dai J, Aaronson SA, and Keller ET (2005). Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65, 7554-7560.
10. 18F-fluoride PET/CT. J Nucl Med 49, 414-421.
11. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, and Vessella RL (2002). Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52, 20-33.
12. Lee Y-P, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, and Lieberman JR (2002). Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62, 5564-5570.
13. Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, and Worland PJ (2005). Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate 65, 347-354.
14. Drake JM, Gabriel CL, and Henry MD (2005). Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 22, 674-684.
15. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, and Navone NM (2004). High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24, 2897-2903.
16. Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do K-A, Han L, and Navone NM (2007). In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 67, 50-60.
17. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, and McCauley LK (2009). A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 69, 1685-1692.
18. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, and McCauley LK (2005). Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146, 1727-1736.
19. Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, et al. (2011). Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 317, 262-275.
20. Morgenstern JP and Land H (1990). Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18, 3587-3596.
21. Singh AS and Figg WD (2005). In vivo models of prostate cancer metastasis to bone. J Urol 174, 820-826.
22. Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, and Geoerger B (2011). The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer 128, 2748-2758.
23. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, and Moul JW (1998). CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160, 459-465.
24. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AAG, Villette J-M, Stower MJ, and Maitland NJ (2002). Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52, 253-263.
25. Kessenbrock K, Plaks V, and Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
26. Zhang L, Shi J, Feng J, Klocker H, Lee C, and Zhang J (2004). Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7, 327-332.
27. Trudel D, Fradet Y, Meyer F, and Têtu B (2010). Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Hum Pathol 41, 1694-1701.
28. Yi B, Williams PJ, Niewolna M, Wang Y, and Yoneda T (2002). Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62, 917-923.
29. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, Furukawa H, Uchida Y, and Watanabe J (2005). Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 184, 1266-1273.
30. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol 75, 239-246.
31. Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, and Clemons M (2009). Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 26, 935-943.
32. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, and Massagué J (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
33. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, and Monzon FA (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7, 64.
34. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, and Rabbani SA (2006). Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289-298.
35. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, and Keller ET (2001). Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47, 212-221.
36. Ding Z, Wu C-J, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273.
37. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, and Weinberg RA (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
38. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, and Stein GS (2006). Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25, 589-600.
39. Chauchereau A (2011). Experimental models for the development of new medical treatments in prostate cancer. Eur J Cancer 47(suppl 3), S200-S214.
40. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, and Lieberman JR (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20, 2189-2199.
41. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, and Lieberman JR (2003). Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21, 62-72.
42. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, and Jacobberger JW (1999). A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
43. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
44. Burger JA and Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767.
45. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, and Ratajczak MZ (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894.
46. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837.
47. Sun Y-X, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20, 318-329.
48. Chabottaux V and Noel A (2007). Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 24, 647-656.
49. Yu T, Wu Y, Helman JI, Wen Y, Wang C, and Li L (2011). CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 9, 161-172.
50. Wang Q, Diao X, Sun J, and Chen Z (2011). Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 35, 897-904.
51. Yeung F, Law WK, Yeh C-H, Westendorf JJ, Zhang Y, Wang R, Kao C, and Chung LWK (2002). Regulation of human osteocalcin promoter in hormoneindependent human prostate cancer cells. J Biol Chem 277, 2468-2476.
52. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, et al. (2010). Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29, 811-821.